×
QQQ   292.45 (-0.73%)
AAPL   141.66 (+0.00%)
MSFT   264.89 (-1.05%)
META   169.49 (-0.39%)
GOOGL   2,316.67 (-1.82%)
AMZN   113.22 (-2.78%)
TSLA   734.76 (-0.32%)
NVDA   168.69 (-1.50%)
NIO   22.95 (-4.69%)
BABA   118.73 (+0.94%)
AMD   86.16 (-1.06%)
MU   58.78 (+0.58%)
CGC   3.79 (+0.53%)
T   20.78 (-1.00%)
GE   66.71 (-0.55%)
F   12.04 (+0.25%)
DIS   96.61 (-1.20%)
AMC   14.13 (+13.31%)
PFE   51.88 (+0.56%)
PYPL   75.94 (-2.24%)
NFLX   189.14 (-0.90%)
QQQ   292.45 (-0.73%)
AAPL   141.66 (+0.00%)
MSFT   264.89 (-1.05%)
META   169.49 (-0.39%)
GOOGL   2,316.67 (-1.82%)
AMZN   113.22 (-2.78%)
TSLA   734.76 (-0.32%)
NVDA   168.69 (-1.50%)
NIO   22.95 (-4.69%)
BABA   118.73 (+0.94%)
AMD   86.16 (-1.06%)
MU   58.78 (+0.58%)
CGC   3.79 (+0.53%)
T   20.78 (-1.00%)
GE   66.71 (-0.55%)
F   12.04 (+0.25%)
DIS   96.61 (-1.20%)
AMC   14.13 (+13.31%)
PFE   51.88 (+0.56%)
PYPL   75.94 (-2.24%)
NFLX   189.14 (-0.90%)
QQQ   292.45 (-0.73%)
AAPL   141.66 (+0.00%)
MSFT   264.89 (-1.05%)
META   169.49 (-0.39%)
GOOGL   2,316.67 (-1.82%)
AMZN   113.22 (-2.78%)
TSLA   734.76 (-0.32%)
NVDA   168.69 (-1.50%)
NIO   22.95 (-4.69%)
BABA   118.73 (+0.94%)
AMD   86.16 (-1.06%)
MU   58.78 (+0.58%)
CGC   3.79 (+0.53%)
T   20.78 (-1.00%)
GE   66.71 (-0.55%)
F   12.04 (+0.25%)
DIS   96.61 (-1.20%)
AMC   14.13 (+13.31%)
PFE   51.88 (+0.56%)
PYPL   75.94 (-2.24%)
NFLX   189.14 (-0.90%)
QQQ   292.45 (-0.73%)
AAPL   141.66 (+0.00%)
MSFT   264.89 (-1.05%)
META   169.49 (-0.39%)
GOOGL   2,316.67 (-1.82%)
AMZN   113.22 (-2.78%)
TSLA   734.76 (-0.32%)
NVDA   168.69 (-1.50%)
NIO   22.95 (-4.69%)
BABA   118.73 (+0.94%)
AMD   86.16 (-1.06%)
MU   58.78 (+0.58%)
CGC   3.79 (+0.53%)
T   20.78 (-1.00%)
GE   66.71 (-0.55%)
F   12.04 (+0.25%)
DIS   96.61 (-1.20%)
AMC   14.13 (+13.31%)
PFE   51.88 (+0.56%)
PYPL   75.94 (-2.24%)
NFLX   189.14 (-0.90%)
NYSEARCA:CNCR

Loncar Cancer Immunotherapy ETF Stock Forecast, Price & News

$15.63
-0.04 (-0.27%)
(As of 06/27/2022 12:00 AM ET)
Add
Today's Range
$15.35
▼
$15.75
50-Day Range
$12.92
▼
$17.22
52-Week Range
$12.76
▼
$32.99
Volume
9,800 shs
Average Volume
7,798 shs
Market Capitalization
$22.66 million
P/E Ratio
N/A
Dividend Yield
11.86%
Price Target
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart

Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Exchange Traded Concepts
Fund NameLoncar Cancer Immunotherapy ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:CNCR
Inception Date10/13/2015
Fund ManagerDenise M. Krisko
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkLoncar Cancer Immunotherapy Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$23.89 million
Average Daily Volume$9.25 thousand
Discount/Premium0.03%

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorExchange Traded Concepts, LLC
CustodianU.S. Bank, N.A.
DistributorQuasar Distributors, LLC
Transfer AgentU.S. Bank, N.A.
Trustee
Lead Market MakerJane Street

Geographic Exposure of CNCR

Currency Exposure of CNCR

Sector Exposure of CNCR

Industry Exposure of CNCR














Loncar Cancer Immunotherapy ETF Frequently Asked Questions

How has Loncar Cancer Immunotherapy ETF's stock price performed in 2022?

Loncar Cancer Immunotherapy ETF's stock was trading at $23.80 at the beginning of the year. Since then, CNCR stock has decreased by 34.3% and is now trading at $15.63.
View the best growth stocks for 2022 here.

Is Loncar Cancer Immunotherapy ETF a good dividend stock?

Loncar Cancer Immunotherapy ETF(NYSEARCA:CNCR) pays an annual dividend of $1.85 per share and currently has a dividend yield of 11.86%. CNCR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.

What other stocks do shareholders of Loncar Cancer Immunotherapy ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Loncar Cancer Immunotherapy ETF investors own include Inovio Pharmaceuticals (INO), ARK Genomic Revolution Multi-Sector ETF (ARKG), VanEck Biotech ETF (BBH), Co-Diagnostics (CODX), Danaher (DHR), Fate Therapeutics (FATE), Gilead Sciences (GILD), GenMark Diagnostics (GNMK), iShares Genomics Immunology and Healthcare ETF (IDNA) and Novavax (NVAX).

What is Loncar Cancer Immunotherapy ETF's stock symbol?

Loncar Cancer Immunotherapy ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "CNCR."

How do I buy shares of Loncar Cancer Immunotherapy ETF?

Shares of CNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Loncar Cancer Immunotherapy ETF's stock price today?

One share of CNCR stock can currently be purchased for approximately $15.63.

How much money does Loncar Cancer Immunotherapy ETF make?

Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR) has a market capitalization of $22.66 million.

This page (NYSEARCA:CNCR) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.